Τίτλος:
Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Waldenström macroglobulinaemia is an indolent B-cell lymphoma with clearly defined criteria for diagnosis, initiation of therapy, and response, which was established by consensus panels at previous International Workshops for Waldenström Macroglobulinaemia (IWWM). The treatment options for Waldenström macroglobulinaemia continued to be researched after the publication of the eighth IWWM consensus recommendations in 2016, and at the tenth IWWM in New York, USA (October, 2018) an international consensus panel was formed to update treatment recommendations. Participants were selected as members of the consensus panel based on their expertise on Waldenström macroglobulinaemia. The initial live discussion took place during the tenth IWWM meeting and two separate teleconferences were held in June, 2019, and January, 2020, to refine recommendations. No external or financial support was received for the elaboration of these recommendations. According to these updated consensus recommendations, alkylating drugs (bendamustine, cyclophosphamide) and proteasome inhibitors (bortezomib, carfilzomib, ixazomib), both in combination with rituximab, as well as BTK inhibitors (ibrutinib), alone or in combination with rituximab, are preferred first-line therapy options for symptomatic patients with Waldenström macroglobulinaemia. In previously treated patients with Waldenström macroglobulinaemia who had an initial durable response, reuse of a previous regimen or another primary therapy regimen are acceptable options. Novel BTK inhibitors (acalabrutinib, zanubrutinib, tirabrutinib) and the BCL2 antagonist venetoclax appear safe and active, and represent emerging options for the treatment of Waldenström macroglobulinaemia. The choice of therapy should be guided by the patient's clinical profile, genomic features, and drug availability. © 2020 Elsevier Ltd
Συγγραφείς:
Castillo, J.J.
Advani, R.H.
Branagan, A.R.
Buske, C.
Dimopoulos, M.A.
D'Sa, S.
Kersten, M.J.
Leblond, V.
Minnema, M.C.
Owen, R.G.
Palomba, M.L.
Talaulikar, D.
Tedeschi, A.
Trotman, J.
Varettoni, M.
Vos, J.M.
Treon, S.P.
Kastritis, E.
Περιοδικό:
The Lancet Haematology
Εκδότης:
Elsevier Ireland Ltd
Λέξεις-κλειδιά:
acalabrutinib; amphotericin B; azacitidine; bendamustine; biosimilar agent; bortezomib; calcium channel blocking agent; carfilzomib; chlorambucil; cladribine; cyclophosphamide; cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine; cytarabine; dexamethasone; diltiazem; doxorubicin; fludarabine; hemoglobin; ibrutinib; idelalisib; immunoglobulin G; immunoglobulin M; influenza vaccine; isoniazid; ixazomib; lenalidomide; methotrexate; monoclonal antibody; obinutuzumab; ofatumumab; prednisone; proteasome; proteasome inhibitor; protein bcl 2; pyrazinamide; recombinant vaccine; ritonavir; rituximab; rivaroxaban; romiplostim; tirabrutinib; tocilizumab; venetoclax; verapamil; vincristine; zanubrutinib; alkylating agent; antineoplastic agent; monoclonal antibody; proteasome inhibitor; protein kinase inhibitor, acute leukemia; acute lymphoblastic leukemia; alkylation; allogeneic hematopoietic stem cell transplantation; alopecia; anemia; arthralgia; atrial fibrillation; bleeding tendency; blood viscosity; cardiovascular disease; consensus; constipation; cryoglobulinemia; disease exacerbation; drug bioavailability; drug safety; dual antiplatelet therapy; electroencephalography; fatigue; fever; gene sequence; graft versus host reaction; headache; heart arrhythmia; hematopoietic stem cell transplantation; human; hypertension; immunoglobulin deficiency; immunosuppressive treatment; leukoencephalopathy; livedo reticularis; maintenance therapy; monotherapy; mortality; multiple myeloma; myelodysplastic syndrome; neuropathy; neutropenia; overall survival; paresthesia; phase 2 clinical trial (topic); plasmapheresis; progression free survival; quality of life; Review; rheumatoid arthritis; Streptococcus pneumoniae; teleconference; thrombocytopenia; tumor lysis syndrome; Waldenstroem macroglobulinemia; workshop; consensus; practice guideline; Waldenstroem macroglobulinemia, Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Consensus; Humans; Practice Guidelines as Topic; Proteasome Inhibitors; Protein Kinase Inhibitors; Waldenstrom Macroglobulinemia
DOI:
10.1016/S2352-3026(20)30224-6
